How to screw up a clinical trial

  • Amarin’s clinical trial of fish oil may be tainted because of suspicions that the placebo group received mineral oil which could affect the absorption of statins. This “anti-statin” effect could raise “bad cholesterol” levels, enhancing the separation of major adverse cardiac events (MACE) between Vascepa and control.
  • Cardiologists who reviewed the data see a big problem with the study that could mean that it exaggerates Vascepa’s benefits.
  • Mineral oil may not not behaved as a placebo at all.
  • Will insurers recommend OTC fish oil?

Continue reading